References(80)
[1]
B. Freddie, F. Jacques, S. Isabelle, R. L. Siegel, L. A. Torre, and J. Ahmedin, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA. Cancer J. Clin., vol. 68, no. 6, pp. 394–424, 2018.
[2]
M. Rugge, R. M. Genta, F. D. Mario, E. M. El-Omar, H. B. El-Serag, M. Fassan, R. H. Hunt, E. J. Kuipers, P. Malfertheiner, K. Sugano, et al., Gastric cancer as preventable disease, Clin. Gastroenterol. Hepatol., .
[3]
Y. Shi, L. Qi, H. Chen, J. Zhang, Q. Guan, J. He, M. Li, Z. Guo, H. Yan, and P. Li, Identification of genes universally differentially expressed in gastric cancer, Biomed Res. Int., .
[4]
E. C. Smyth, M. Nilsson, H. I. Grabsch, N. C. V. Grieken, and F. Lordick, Gastric cancer, The Lancet, .
[5]
J. Machlowska, J. Baj, M. Sitarz, R. Maciejewski, and R. Sitarz, Gastric cancer: Epidemiology, risk factors, classification, genomic characteristics and treatment strategies, International Journal of Molecular Sciences, .
[6]
A. R. Yusefi, K. B. Lankarani, P. Bastani, M. Radinmanesh, and Z. Kavosi, Risk factors for gastric cancer: A systematic review, Asian Pacific Journal of Cancer Prevention, .
[7]
G. Herrera-Almario and V. E. Strong, Minimally invasive gastric surgery, Ann. Surg. Oncol., .
[8]
J. Tey, Y. Y. Soon, W. Y. Koh, C. N. Leong, B. Vellayappan, K. Lim, and I. W. K. Ivan, Palliative radiotherapy for gastric cancer: A systematic review and meta-analysis, Oncotarget, .
[9]
O. Zhandossov, G. Kaussova, and A. Koten, Combined treatment for gastric cancer: Immunological approach, Turkish J. Gastroenterol., .
[10]
E. Niccolai, A. Taddei, D. Prisco, and A. Amedei, Gastric cancer and the epoch of immunotherapy approaches, World J. Gastroenterol., .
[11]
L. Necula, L. Matei, D. Dragu, A. I. Neagu, C. Mambet, S. Nedeianu, C. Bleotu, C. C. Diaconu, and M. Chivu-Economescu, Recent advances in gastric cancer early diagnosis, World J. Gastroenterol., .
[12]
A. S. Crystal, A. T. Shaw, L. V. Sequist, L. Friboulet, M. J. Niederst, E. L. Lockerman, R. L. Frias, J. F. Gainor, A. Amzallag, P. Greninger, et al., Patient-derived models of acquired resistance can identify effective drug combinations for cancer, Science, .
[13]
A. A. Borisy, P. J. Elliott, N. W. Hurst, M. S. Lee, J. Lehar, E. R. Price, G. Serbedzija, G. R. Zimmermann, M. A. Foley, B. R. Stockwell, et al., Systematic discovery of multicomponent therapeutics, Proc. Natl. Acad. Sci., .
[14]
B. Klinger, A. Sieber, R. Fritsche-Guenther, F. Witzel, L. Berry, D. Schumacher, Y. Yan, P. Durek, M. Merchant, R. Schafer, et al., Network quantification of EGFR signaling unveils potential for targeted combination therapy, Mol. Syst. Biol., .
[15]
M. Bansal, J. Yang, C. Karan, M. P. Menden, J. C. Costello, H. Tang, G. Xiao, Y. Li, J. Allen, R. Zhong, et al., A community computational challenge to predict the activity of pairs of compounds, Nat. Biotechnol., .
[16]
L. A. M. Griner, R. Guha, P. Shinn, R. M. Young, J. M. Keller, D. Liu, I. S. Goldlust, A. Yasgar, C. MaKnight, M. B. Boxer, et al., High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells, Proc. Natl. Acad. Sci., .
[17]
M. L. Miller, E. J. Molinelli, J. S. Nair, T. Sheikh, R. Samy, X. Jing, Q. He, A. Korkut, A. M. Crago, S. Singer, et al., Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets, Sci. Signal., .
[18]
Y. Tu, Q. Wu, J. He, J. Xu, S. Yu, Q. Wang, Y. Cheng, Q. Yang, S. Xu, and Y. Cao, Exploring the potential molecular mechanism of scutellaria baicalensis georgi in the treatment of gastric cancer based on network pharmacological analysis and molecular docking technology, Front. Pharmacol., .
[19]
L. Guo, H. Shi, and L. Zhu, Siteng fang reverses multidrug resistance in gastric cancer: A network pharmacology and molecular docking study, Front. Oncol., .
[20]
O. A. Kolawole, F. Olatomide A., and S. Banjo, Anti-gastric cancer activity of 1,2,3-triazolo[4,5-d]pyrimidine hybrids (1,2,3-TPH): QSAR and molecular docking approaches, Heliyon, .
[21]
K. Li, Y. Du, L. Li, and D. -Q. Wei, Bioinformatics approaches for anti-cancer drug discovery, Curr. Drug Targets, vol. 21, no. 1, pp. 3–17, 2019.
[22]
A. C. Kaushik, Y. J. Wang, X. Wang, and D. -Q. Wei, Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations, Brief. Bioinform., .
[23]
M. Ö. Cingiz, G. Biricik, and B. Diri, The performance comparison of gene co-expression networks of breast and prostate cancer using different selection criteria, Interdiscip. Sci.: Comput. Life Sci., vol. 13, no. 3, pp. 500–510, 2021.
[24]
D. Szklarczyk, A. L. Gable, D. Lyon, A. Junge, S. Wyder, J. Huerta-Cepas, M. Simonovic, N. T. Doncheva, J. H. Morris, P. Bork, et al., STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets, Nucleic Acids Res., .
[25]
R. K. Patel and M. Jain, NGS QC toolkit: A toolkit for quality control of next generation sequencing data, PLoS One, .
[26]
H. Li and R. Durbin, Fast and accurate short read alignment with burrows-wheeler transform, Bioinformatics, .
[27]
Y. Liao, G. K. Smyth, and W. Shi, Featurecounts: An efficient general purpose program for assigning sequence reads to genomic features, Bioinformatics, .
[28]
Z. Li, P. Hou, D. Fan, M. Dong, M. Ma, H. Li, R. Yao, B. Huang, G. Wang, P. Geng, et al., The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer, Cell Death Differ., vol. 24, no. 1, pp. 59–71, 2017.
[29]
E. D. Tetzlaff, P. Cen, and J. A. Ajani, Emerging drugs in the treatment of advanced gastric cancer, Expert Opinion on Emerging Drugs, .
[30]
L. Vecchione, M. Orditura, F. Ciardiello, and F. D. Vita, Novel investigational drugs for gastric cancer, Expert Opinion on Investigational Drugs, .
[31]
R. Geng, L. Song, J. Li, and L. Zhao, The safety of apatinib for the treatment of gastric cancer, Expert Opin. Drug Saf., .
[32]
D. A. Hescheler, P. S. Plum, T. Zander, A. Quaas, M. Korenkov, A. Gassa, M. Michel, C. J. Bruns, and H. Alakus, Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data, Gastric Cancer, .
[33]
M. I. Love, W. Huber, and S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol., .
[34]
P. Shannon, A. Markiel, O. Ozier, N. S. Baliga, J. T. Wang, D. Ramage, N. Amin, B. Schwikowski, and T. Ideker, Cytoscape: A software environment for integrated models of biomolecular interaction networks, Genome Res., .
[35]
D. W. Huang, B. T. Sherman, and R. A. Lempicki, Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists, Nucleic Acids Res., .
[36]
Z. Tang, B. Kang, C. Li, T. Chen, and Z. Zhang, GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis, Nucleic Acids Res., .
[37]
M. V. Kuleshov, M. R. Jones, A. D. Rouillard, N. F. Fernandez, Q. Duan, Z. Wang, S. Koplev, S. L. Jenkins, K. M. Jagodnik, A. Lachmann, et al., Enrichr: A comprehensive gene set enrichment analysis web server 2016 update, Nucleic Acids Res., .
[38]
J. Pinero, J. M. Ramírez-Anguita, J. Saüch-Pitarch, F. Ronzano, E. Centeno, F. Sanz, and L. I. Furlong, The DisGeNET knowledge platform for disease genomics: 2019 update, Nucleic Acids Res., .
[39]
H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov, and P. E. Bourne, The protein data bank, Nucleic Acids Research, .
[40]
A. Waterhouse, M. Bertoni, S. Bienert, G. Studer, G. Tauriello, R. Gumienny, F. T. Heer, T. A. P. D. Beer, C. Rempfer, L. Bordoli, et al., SWISS-MODEL: Homology modelling of protein structures and complexes, Nucleic Acids Res., .
[41]
S. Kim, J. Chen, T. Cheng, A. Gindulyte, J. He, S. He, Q. Li, B. A. Shoemaker, P. A. Thiessen, B. Yu, et al., PubChem 2019 update: Improved access to chemical data, Nucleic Acids Res., .
[43]
T. J. Dolinsky, P. Czodrowski, H. Li, J. E. Nielsen, J. H. Jensen, G. Klebe, and N. A. Baker, PDB2PQR: Expanding and upgrading automated preparation of biomolecular structures for molecular simulations, Nucleic Acids Res., .
[44]
J. C. Gordon, J. B. Myers, T. Folta, V. Shoja, L. S. Heath, and A. Onufriev, H++: A server for estimating pKas and adding missing hydrogens to macromolecules, Nucleic Acids Res., .
[45]
G. M. Morris, R. Huey, W. Lindstrom, M. F. Sanner, R. K. Belew, D. S. Goodsell, and A. J. Olson, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, J. Comput. Chem., vol. 30, no. 16, pp. 2785–2791, 2009.
[46]
O. Trott and A. J. Olson, AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comput. Chem., vol. 31, no. 2, pp. 455–461, 2010.
[50]
O. M. Omar, M. Soutto, N. S. Bhat, A. A. Bhat, H. Lu, Z. Chen, and W. El-Rifai, TFF1 antagonizes TIMP-1 mediated proliferative functions in gastric cancer, Mol. Carcinog., vol. 57, no. 11, pp. 1577–1587, 2018.
[51]
W. Chen and Z. Yang, Identification of differentially expressed genes reveals BGN predicting overall survival and tumor immune infiltration of gastric cancer, Comput. Math. Methods Med., .
[52]
T. Chen, L. Sun, C. He, Y. Gong, Q. Xu, and Y. Yuan, Serum OPN expression for identification of gastric cancer and atrophic gastritis and its influencing factors, PLoS One, .
[53]
D. Oikonomou, K. Hassan, J. T. Kaifi, H. C. Fiegel, P. G. Schurr, U. Reichelt, K. Aridome, E. F. Yekebas, O. Mann, D. Kluth, et al., Thy-1 as a potential novel diagnostic marker for gastrointestinal stromal tumors, J. Cancer Res. Clin. Oncol., vol. 133, no. 12, pp. 951–955, 2007.
[54]
Y. C. Chuang, H. -Y. Wu, Y. -L. Lin, S. -C. Tzou, C. -H. Chuang, T. -Y. Jian, P. -R. Chen, Y. -C. Chang, C. -H. Lin, T. -H. Huang, et al., Blockade of ITGA2 induces apoptosis and inhibits cell migration in gastric cancer, Biol. Proced. Online, .
[55]
S. Soleyman-Jahi, S. Nedjat, A. Abdirad, N. Hoorshad, R. Heidari, and K. Zendehdel, Prognostic significance of matrix metalloproteinase-7 in gastric cancer survival: A meta-analysis, PLoS One, .
[56]
J. Qiu, M. Sun, Y. Wang, and B. Chen, Identification of hub genes and pathways in gastric adenocarcinoma based on bioinformatics analysis, Med. Sci. Monit., .
[57]
B. Jiang, S. Li, Z. Jiang, and P. Shao, Gastric cancer associated genes identified by an integrative analysis of gene expression data, Biomed Res. Int., .
[58]
X. Chong, R. Peng, Y. Sun, L. Zhang, and Z. Zhang, Identification of key genes in gastric cancer by bioinformatics analysis, Biomed Res. Int., .
[59]
W. Wang, Y. He, Q. Zhao, X. Zhao, and Z. Li, Identification of potential key genes in gastric cancer using bioinformatics analysis, Biomed. Reports, vol. 12, no. 4, pp. 178–192, 2020.
[60]
K. Hu and F. Chen, Identification of significant pathways in gastric cancer based on protein-protein interaction networks and cluster analysis, Genet. Mol. Biol., vol. 35, no. 3, pp. 701–708, 2012.
[61]
D. Mao, R. Xu, H. Chen, X. Chen, D. Li, S. Song, Y. He, Z. Wei, and C. Zhang, Cross-talk of focal adhesion-related gene defines prognosis and the immune microenvironment in gastric cancer, Front. Cell Dev. Biol., .
[62]
T. Matsuoka and M. Yashiro, The role of PI3K/Akt/mTOR signaling in gastric carcinoma, Cancers, vol. 6, no. 3, pp. 1441–1463, 2014.
[63]
S. Luo, R. Lin, X. Liao, D. Li, and Y. Qin, Identification and verification of the molecular mechanisms and prognostic values of the cadherin gene family in gastric cancer, Sci. Rep., vol. 11, no. 1, p. 23674, 2021.
[64]
R. Huang, W. Gu, B. Sun, and L. Gao, Identification of COL4A1 as a potential gene conferring trastuzumab resistance in gastric cancer based on bioinformatics analysis, Mol. Med. Rep., vol. 17, no. 5, pp. 6387–6396, 2018.
[65]
Y. L. Ding, S. F. Sun, and G. L. Zhao, COL5A2 as a potential clinical biomarker for gastric cancer and renal metastasis, Medicine (Baltimore)., vol. 100, no. 7, p. e24561, 2021.
[66]
X. Liu and S. J. Meltzer, Gastric cancer in the era of precision medicine, CMGH, vol. 3, no. 3. pp. 348–358, 2017.
[67]
G. A. Colditz, National cancer institute, SAGE Encycl. Cancer Soc., .
[68]
T. Lim, J. Lee, D. J. Lee, H. Y. Lee, B. Han, K. K. Baek, H. K. Ahn, S. J. Lee, S. H. Park, J. O. Park, et al., Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer, Cancer Chemother. Pharmacol., vol. 68, no. 1, pp. 255–262, 2011.
[69]
C. Pauligk, S. Janowski, K. Steinmetz, A. Atmaca, A. Pustowka, E. Jaeger, and S. Al-Batran, Daily RAD001 plus mitomycin C, every three weeks in previously treated patients with advanced gastric cancer or cancer of the esophagogastric junction: Preliminary results of a phase I study, J. Clin. Oncol., vol. 28, no. 15_suppl, p. e14531, 2010.
[70]
T. Doi, K. Muro, N. Boku, Y. Yamada, T. Nishina, H. Takiuchi, Y. Komatsu, Y. Hamamoto, N. Ohno, and Y. Fujita, Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer, J. Clin. Oncol., vol. 28, no. 11, pp. 1904–1910, 2010.
[71]
E. V. Cutsem, C. Boni, J. Tabernero, B. Massuti, G. Middleton, F. Dane, P. Reichardt, F. L. Pimentel, A. Cohn, P. Follana, et al., Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: A randomized phase II study, Ann. Oncol., vol. 26, no. 1, pp. 149–156, 2015.
[72]
H. Lin, D. Han, G. Fu, C. Liu, L. Wang, S. Han, B. Liu, and J. Yu, Concurrent apatinib and docetaxel vs apatinib monotherapy as third-or subsequent-line therapy for advanced gastric adenocarcinoma: A retrospective study, Onco. Targets. Ther., vol. 12, pp. 1681–1689, 2019.
[73]
E. M. Wolin, A. Manon, C. Chassaing, A. Lewis, L. Bertocchi, J. Richard, and A. T. Phan, Lanreotide depot: An antineoplastic treatment of carcinoid or neuroendocrine tumors, Journal of Gastrointestinal Cancer, vol. 47, no. 4. pp. 366–374, 2016.
[74]
A. J. Souers, J. D. Leverson, E. R. Boghaert, S. L. Ackler, N. D. Catron, J. Chen, B. D. Dayton, H. Ding, S. H. Enschede, W. J. Fairbrother, et al., ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, Nat. Med., vol. 19, no. 2, pp. 202–208, 2013.
[75]
H. Fukamachi, S. -K. Kim, J. Koh, H. S. Lee, Y. Sasaki, K. Yamashita, T. Nishikawaji, S. Shimada, Y. Akiyama, S. J. Byeon, et al., A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors, J. Exp. Clin. Cancer Res., .
[76]
S. J. Byeon, N. Han, J. Choi, M. A. Kim, and W. H. Kim, Prognostic implication of TSC1 and mTOR expression in gastric carcinoma, J. Surg. Oncol., vol. 109, no. 8, pp. 812–817, 2014.
[77]
S. E. Al-Batran, M. Ducreux, and A. Ohtsu, MTOR as a therapeutic target in patients with gastric cancer, International Journal of Cancer, vol. 130, no. 3. pp. 491–496, 2012.
[78]
T. Murayama, M. Inokuchi, Y. Takagi, H. Yamada, K. Kojima, J. Kumagai, T. Kawano, and K. Sugihara, Relation between outcomes and localisation of p-mTOR expression in gastric cancer, Br. J. Cancer, vol. 100, no. 5, pp. 782–788, 2009.
[79]
T. Huang, F. Zhou, X. Yuan, T. Yang, X. Liang, Y. Wang, H. Tu, J. Chang, K. Nan, and Y. Wei, Reactive oxygen species are involved in the development of gastric cancer and gastric cancer-related depression through ABL1-mediated inflammation signaling pathway, Oxid. Med. Cell. Longev., .
[80]
N. Kassem, O. M. Ismail, H. Elomri, and M. A. Yassin, Nilotinib induced recurrent gastric polyps: Case report and review of literature, American Journal of Case Reports, vol. 18, pp. 794–798, 2017.